SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to widespread discussion around year-end tax loss selling and persistent selling from early investors, which is currently driving significant downward pressure. Community sentiment remains sharply divided, with some seeing current levels as a compelling buying opportunity given the company's profitability and growth, while others emphasize ongoing dilution concerns and a challenging market backdrop.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to the recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in over four decades. The community is actively discussing its potential to alleviate GLP-1 induced nausea, viewing this as a significant market opportunity and a catalyst for potential buyouts. While some initially expressed mixed reactions to price action, many believe the stock's long-term value and additional pipeline catalysts are not yet fully reflected.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending amidst intense speculation regarding an unconfirmed FDA decision on its relacorilant drug for Cushing's Syndrome, with community chatter divided between rumored rejection causing panic selling and calls to buy the dip. The immediate uncertainty around this key pipeline asset, alongside its existing revenue-generating drug Korlym and other promising indications like ovarian cancer, fuels a volatile debate among investors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing heightened volatility as the CME implements multiple margin requirement hikes, fueling intense community debate over market manipulation. Many perceive these actions as a concerted effort to suppress prices and liquidate leveraged positions, especially with reported disparities between paper and physical silver values globally. Despite calls of a "rigged game" and comparisons to past crashes, a strong bullish contingent anticipates a significant long-term rally driven by robust industrial demand and ongoing concerns about supply.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to high anticipation for upcoming FDA decisions regarding AXS-05 for Alzheimer's agitation and AXS-12 for narcolepsy, with the community optimistic about potential approvals. This regulatory excitement is complemented by strong, consistent prescription growth and expanding market access for its major depressive disorder treatment, Auvelity. Investors are keenly focused on these catalysts and the company's broader CNS pipeline, despite some impatience with communication around timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In an update on Monday afternoon, the company said it is seeing signs of recovery for admin and POS login issues after deploying a fix for login issues at around 12:20 EST.</li><li>Later in the evening at around 17:00 EST, the company reiterated that they are continuing to monitor the recovery of the issue and will update once it has new information.</li><li>For Shopify, the outage coincided with Cyber Monday, a day of online sales that falls on the Monday after the U.S. Thanksgiving weekend. &nbsp; &nbsp;</li></ul> Shares of Shopify (SHOP) edged up 0.6% in after-hours on Monday as signs of recovery followed its Cyber Monday outage, even as the stock had closed the regular session down 6%.The Canadian e-commerce company said on Monday morning &nbsp;at around 9:47 EST that merchants may experience issues when trying to login to Shopify and also when logging into point-of-sale systems or attempting to contact support. A point of sale, or POS, is a system used to process transactions and accept payments in person.<h2 class="st-heading-2">Company Deploys Fix Over Hours</h2>In an update on Monday afternoon, the company said it is seeing signs of recovery for admin and POS login issues after deploying a fix for login issues at around 12:20 EST.“We have found and fixed an issue with our login authentication flow, and are seeing signs of recovery for admin and POS login issues now. We are continuing to monitor recovery,” the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shopifystatus.com/">said</a> in an update at 14:31 EST.Later in the evening at around 17.00 EST, the company reiterated that they are continuing to monitor the recovery of the issue and will update once it has new information.According to data from Downdetector, Shopify outage reports touched a high of over 4000 on Monday morning around 11:00 am EST before tapering down through the day. &nbsp;For Shopify, the outage coincided with Cyber Monday, a day of online sales that falls on the Monday after the U.S. Thanksgiving weekend. On Black Friday, the company’s global sales had hit $6.2 billion, up 25% from last year. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SHOP stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user highlighted that the day was one of their biggest revenue reaping ones. “I wonder how big the hit will be to the bottom line,” they wrote.<stembedurl>https://stocktwits.com/Timmiee/message/637837465</stembedurl><a href="https://stocktwits.com/symbol/SHOP">SHOP stock</a> has gained over 40% this year and by about 32% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/instagram-chief-wants-staff-to-return-to-office-full-time-report/cLI7oYXRE0d">Instagram Chief Wants Staff To Return To Office Full Time: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shopify topped analyst expectations on earnings and revenue while also announcing an upbeat forecast for the third quarter.

Shopify Stock Rises After Hours As Recovery Signs Emerge From Cyber Monday Meltdown

The Canadian e-commerce company said on Monday morning at around 9:47 EST that merchants may experience issues when trying to login to Shopify and also when logging into point-of-sale systems or attempting to contact support.

Equity

<ul class="summary-bullets"><li>Brady said that the Prime members have received over €6 million in fare discounts, so “this trial has cost more money than it generates.”</li><li>All existing Prime members will continue to enjoy exclusive monthly low-fare offers until October 2026, but no new members will be allowed to sign up after Friday.</li><li>According to Ryanair’s website, the Prime members get free reserved seats, free travel insurance and access to 12 member-only seat sales and one each month.</li></ul>Ryanair (RYAAY) announced on Friday that it will close its prime member offering from November, following an eight-month trial period during which the European airline noted that the membership cost more than it generated.Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 Prime members, generating over €4.4 million ($5.1 million) in subscription fees. However, Prime members have received over €6 million in fare discounts, so “this trial has cost more money than it generates,” Brady said,The company said that all existing Prime members will continue to enjoy exclusive monthly low-fare offers until October 2026, but no new members will be allowed to sign up after Friday.<h2 class="st-heading-2">Ryanair Prime Membership Details</h2>According to Ryanair’s website, Prime members get free reserved seats, free travel insurance, and access to 12 member-only seat sales, one each month. Prime members get the offer for £79 per annum.Ryanair noted that, based on a passenger who flew 12 times last year, the potential savings so far from the membership were £640 per year. The company added that for a passenger who flew three times last year, the potential savings so far were £415.<h2 class="st-heading-2">Brady’s View</h2>Brady noted that existing Prime members will be allowed to use their seat savings for the remainder of their 12-month membership.“This level of memberships, or subscription revenue does not justify the time and effort it takes to launch monthly exclusive Prime seat sales for our 55,000 Prime members,” Brady said.&nbsp;&nbsp;He noted that the airline has had over 207 million passengers this year and said that they would be trying to offer the lowest fares in Europe to&nbsp;all its customers, and not the subset of 55,000 Prime members.Retail sentiment on <a href="https://stocktwits.com/symbol/RYAAY">Ryanair</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.U.S.-listed shares of the company have gained nearly 57% this year.€1 = $1.16For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/abercrombie-fitch-catches-retail-attention-after-barclays-raises-price-target-on-hollister-momentum/cL5abTzRELe">Abercrombie &amp; Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum</a>

Ryanair Boeing 737 MAX 8 as seen during taxiing, take off and flying phase in Eindhoven Airport.

Ryanair Pulls Plug On Prime Membership Offering After Trial Proves Too Costly 

Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 prime members, generating over €4.4 million in subscription fees.

Cloudflare Inc. (NET) stock surged over 5% in midday trading on Thursday after Goldman Sachs issued a double upgrade on its shares.The brokerage revised its rating to ‘Buy’ from ‘Sell’ and nearly doubled the price target from $77 to $140, citing expectations of significant growth in 2025 driven by operational improvements and new market opportunities, as per TheFly.Goldman Sachs analyst Gabriela Borges highlighted “several positive catalysts” for Cloudflare’s future success, citing improved sales and marketing productivity as a key driver.&nbsp;The research note pointed to improvements from changes spearheaded by Marc Boroditsky, the former Chief Revenue Officer of Twilio and Okta, who joined Cloudflare in November 2022.&nbsp;Boroditsky introduced a revamped go-to-market strategy in early 2023, designed to better position Cloudflare’s platform for enterprise adoption.Goldman Sachs cited industry conversations suggesting that artificial intelligence is moving more materially from training to inferencing use cases, consistent with Cloudflare's&nbsp;third-quarter (Q3) comments.At its core, the analysts argued, Cloudflare has built “a unique globally distributed cloud platform” that offers a range of network services to businesses.“This architecture allows new products to be deployed at low incremental cost and monetized at high incremental margin,” the analysts wrote.Goldman believes Cloudflare will see success as it rolls out developer services and production environment tools, with a path to monetization becoming “more tangible.”<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_01_02_123203_07aa377fd3.png" alt="Screenshot 2025-01-02 123203.png">On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/NET">Cloudflare’s stock</a> flipped to ‘extremely bullish’ from ‘bearish’ a day ago, as chatter surged to ‘extremely high’ levels.One user&nbsp;expects other brokerages&nbsp;to follow suit after Goldman Sachs’ upgrade. <a href="https://stocktwits.com/The_Reaper/message/598520907">https://stocktwits.com/The_Reaper/message/598520907</a>Others predicted that it’s going be a bullish year for the stock. <a href="https://stocktwits.com/eddyborja/message/598572382">https://stocktwits.com/eddyborja/message/598572382</a><a href="https://stocktwits.com/Dostovy/message/598526527">https://stocktwits.com/Dostovy/message/598526527</a>Despite the optimism, analysts noted competitive risks from hyperscalers with larger resources and networks.&nbsp;They also flagged potential vulnerabilities related to service outages, referencing a significant June 2022 incident that temporarily disrupted major websites like Shopify and Coinbase.Cloudflare's stock performance in 2024 was tepid, ending the year down nearly 2%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kopin-stock-gains-on-buy-rating-from-canaccord/cW6v4OIRlI">Kopin Stock Pops On ‘Buy’ Rating From Canaccord: Retail Remains Undecided</a>

Cloudflare Stock Jumps On Goldman Sachs Double Upgrade, Price Target Hike: Retail Ecstatic

Goldman Sachs analyst Gabriela Borges highlighted “several positive catalysts” for Cloudflare’s future success, citing improved sales and marketing productivity as a key driver. 

CGGR
Capital Group Companies Inc - Capital Group Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest CGGR News

CGGRCapital Group Companies Inc - Capital Group Growth ETF